15-ethenyl-13-methyl-19-oxa-3,13-diazahexacyclo[14.3.1.02,10.04,9.010,15.012,17]icosa-2,4,6,8-tetraene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 15-ethenyl-13-methyl-19-oxa-3,13-diazahexacyclo[14.3.1.02,10.04,9.010,15.012,17]icosa-2,4,6,8-tetraene
• 化学式: C₂₀H₂₂N₂O
• 分子量: 306.4
• InChiKey: VTLYEMHGPMGUOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  24.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• USE OF KOUMINE AND ITS HOMOLOGUES IN PREPARATION OF MEDICAMENT FOR TREATMENT OF AUTOIMMUNE DISEASES OF INVOLVED BONES AND JOINTS
  申请人：Fujian Medical University

  公开号：US20150011767A1

  公开（公告）日：2015-01-08

  The present invention discloses an application of koumine and homologue thereof in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like, in particular an application of Gelsemium alkaloid monomer koumine and homologue thereof or pharmaceutically acceptable salt thereof as active ingredient in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like. The result of pharmacology experiment shows that koumine can decrease the generation of organism antibody against autoimmune diseases involving bones and joints in a dose dependent manner, improve symptoms of swelling and hyperalgesia, reduce arthritis index, reverse joint pathological changes, and has no serious shortage of commonly used clinical drugs; thus koumine has an effect against autoimmune diseases involving bones and joints including rheumatoid arthritis, ankylosing spondylitis etc. with strong potency and low toxicity. Koumine can be developed into a new drug for treating autoimmune disease involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica etc., which has a clear industrial prospect.
• US9078890B2
  申请人：——

  公开号：US9078890B2

  公开（公告）日：2015-07-14